The Role of Tumor Mutational Burden in Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Linda Bosserman provides an overview of the nuances of personalized medicine as it relates to cost, value and access
Listen as Dr. Mesa presents his opinion on the success of cytoreductive therapy with patients with polycythemia vera.Supported through funding from Incyte